POLICYBZR

PB Fintech share price & results

PB Fintech Limited· Financial Services

Results to
Sept 2026
Latest analysed call
Q2 FY27
Ownership as of
Sept 2026

India's largest online insurance & credit marketplace, operating Policybazaar and Paisabazaar.

Company research is public. Sign in to keep your own companies, notes and cases.

Inve AI Signals on POLICYBZR
Direct bridge to live research & tools watching PB Fintech Limited
Guidance Hit Rate
14 targets · 0% hit rate 0 achieved · 10 active →
Segment Shift
2 segments tracked See revenue & margin mix below →
Reverse DCF
Implied Growth Test priced-in growth in DCF tool →
Concall & Tone
Q2 FY27 analysed Read claims, qualifiers & Q&A →

Price & Snapshot

₹953.8 −1.37% · −₹13.2

Last close 9 Nov 2026 · NSE · INR · Source: Inve

Performance −46.5% 1Y

₹1.0k₹1.2k₹1.4k₹1.6k₹1.8k₹2.0kNov 25Dec 25Feb 26Mar 26May 26Jun 26Aug 26Sept 26Nov 26Q3 FY26 — 2 Feb 2026Q4 FY26 — 6 May 2026Q1 FY27 — 5 Aug 2026Q2 FY27 — 30 Oct 2026

1Y: ₹1,783.8 on 7 Nov 2025 → ₹953.8. High ₹1,957.3 (9 Dec 2025), low ₹928 (3 Nov 2026).

Previous close
₹967
Market cap
₹44.7k Cr
52-week range
₹928 – ₹1,957.3
One year
−46.97%
Price to earnings (TTM to Sept 2026)
55.47×
Return on equity (TTM to Sept 2026)
10.35%

Reported

Key financial metrics & valuation ratios

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue-89.0 ₹ crore−387.1% YoYQuarterly, as filedQuarter to Sept 2026Revenue from operations as filed.
Operating margin-478.0 %−377.0 pts YoYOperating profit / revenueQuarter to Sept 2026For the quarter; a change is in percentage points.
Net profit13.0 ₹ crore+1200.0% YoYQuarterly, as filedQuarter to Sept 2026Profit after tax as filed.
Return on equity10.35 %+4.8 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026
Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin-0.54 %+5.1 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026
(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)37.07 %−8.3 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026
Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Sept 2026

Business Mix

Where revenue comes from

Insurance broker services grew from 84% to 92% of revenue over the last two years.

Insurance broker services 91.5% · ₹1,728.44 Cr +45.6% YoY
Other services 8.5% · ₹159.84 Cr −0.7% YoY

Explore full multi-period segment shift & margins →

Guidance

What management said, and what became of it

0 of 4 judged targets kept · 10 open · verdicts reflect calls analysed to Q2 FY27.

PB Fintech Limited management guidance track record on Inve: 14 targets tracked across analysed earnings calls (0 achieved, 4 missed, 10 open).

Watch execution in Growth & Demand (1 on track · 1 delayed/missed).

TargetOriginal wordingSaidLatest callVerdict
Growth Fixed Costs Growth
It will grow at maybe about 2/3rd of our revenue growth or so.
Call transcript, Q1 FY26 · 1 Aug 2025
Q1 FY26
Q2 FY27:No specific data on fixed cost growth provided; management cited qualitative cost levers (curtailed October hiring, AI productivity) without reporting the ratio.
Call transcript, Q2 FY27 · 30 Oct 2026
Ghosted
Growth Revenue CAGR
From a long-term perspective, we believe 30% is the right CAGR for us to sort of plan for.
Call transcript, Q4 FY25 · 16 May 2025
Q4 FY25
Q2 FY27:Consolidated operating revenue grew 35% YoY to ₹2,178 Cr, tracking ahead of the 30% long-term CAGR target despite demand softness.
Call transcript, Q2 FY27 · 30 Oct 2026
On Track

Source: Inve Guidance Tracker for PB Fintech Limited · to Q2 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

4 of PB Fintech Limited's 14 targets were missed. See which ones, and which are quietly gone. The 2 above are the free sample; 12 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Supply chain

Cross-company call evidence

Named counterparties and similar headwinds disclosed on earnings calls.

Products, transactions and disclosed impact

Company disclosures with supporting evidence. Actual results, management expectations, and summary paraphrases remain qualified by source basis.

  • Acquisition Stage: Closed / completed Call date: 2025-05-16
    1. Proposed
    2. Announced
    3. Active
    4. Completed / ended

    Named counterparties & directional relationship

    PB Fintech Limited → acquires → Unnamed Healthcare Asset

    Party roles: Acquirer / Transaction asset · Closed / completed · Definitive agreement

    Counterparty named; listed-company identity not verified.

    Products, services & business exposure Mentioned in this disclosure
    Unnamed Healthcare Asset · role: Transaction asset · category: Business asset
    Additional disclosure context
    Rationale: Part of long-term healthcare strategy to solve customer pain points and integrate hospitals.
    Consideration form: Consideration form recorded as undisclosed, amount null; speaker says the asset was paid for.
    Funding mention: Speaker says the round has happened and the money has come in; mentioned alongside the asset acquisition, relationship between the two not given.
    Future plan: Looking to do the same with maybe 3-4 other assets; prospective, not part of the closed acquisition.
    Future plan: Of five hospitals being looked at in NCR, probably buy 2-3 operating ones and 2-3 shells to be converted rapidly into operating hospitals; prospective, no specific targets named.
    Evidence and remaining questions (Contextual assertion review)

    Call date: 2025-05-16 · Review status: Contextual assertion review · Policy: context-loop-v2

    Summary paraphrase

    we've acquired one asset, in the sense we paid for it, we've taken it over

    Summary paraphrase

    Unnamed Healthcare Asset: we've acquired one asset, in the sense we paid for it, we've taken it over

    Summary paraphrase

    Part of long-term healthcare strategy to solve customer pain points and integrate hospitals.

    Summary paraphrase

    undisclosed

    Summary paraphrase

    We've had the round, we've had the money come in

    Summary paraphrase

    We are looking to do the same with maybe 3-4 other assets

    Summary paraphrase

    five hospitals that we're looking at in NCR, we'll probably buy 2-3 operating ones, and 2-3 more like shells which we are going to convert rapidly into operating hospitals

    Not established by the available evidence

    • target identity: Target is only described as 'Unnamed Healthcare Asset'; name and legal form of the acquired entity or asset are not given.
    • seller: No seller or owner of the acquired asset is stated.
    • acquisition vehicle: First-person 'we' binds to PB Fintech Limited, but the exact legal entity that acquired the asset is not stated.
    • asset nature: Record calls it a healthcare asset and the rationale mentions integrating hospitals, but it does not say the acquired asset is a hospital, entity or business; mapped to BUSINESS_ASSET/UNDETERMINED.
    • consideration amount: Consideration form is undisclosed and amount is null; no value, stake or valuation stated.
    • event date: No completion date given; call_date and report_date are disclosure/reporting dates, not the event date, so effective_time_text is null.
    • asset location: NCR is stated only for the five hospitals under consideration, not for the acquired asset, so geography is null.
    • transcript confirmation: No transcript passages supplied; closed status and acquisition rest on the summary record and its source_quote only.
    • funding round to acquisition: The funding round and the acquisition are mentioned together; no link, such as use of proceeds, is stated.

From available earnings-call summaries. Disclosures are management statements, not independently verified transactions.

Live Summary

POLICYBZR ₹953.8 −1.37%
Guidance Verdict (14 tracked) 0 kept · 10 open· 4 missed
AI Call Brief · Q2 FY27

PB Fintech Limited Q2 FY27

Overview

Symbol
NSE:POLICYBZR
Exchange
NSE
Currency
INR

What PB Fintech Limited does

Based on the company's own presentations, annual report and earnings calls.

PB Fintech operates two consumer-facing digital marketplaces — Policybazaar for insurance comparison and distribution across health, term life, motor, travel and other lines, and Paisabazaar for credit products including personal loans, credit cards and credit-score tracking — that connect retail and corporate customers with insurer and lending partners. It earns commission from these partners on policies sold and credit disbursed, plus a growing renewal ("trail") revenue stream as previously sold insurance policies persist. The company also runs PB Partners, an offline point-of-sale agent network, and newer businesses including PB Health (a hospital network), corporate insurance broking, and a cross-border insurance business in the UAE through subsidiary PB Fintech FZ-LLC.

Segments

  • Insurance Marketplace (Policybazaar)
  • Credit Marketplace (Paisabazaar)
  • New Initiatives
Registered consumers (cumulative)
145.7 Mn
Insurance policies sold (cumulative)
67.3 Mn
Unique transacting insurance customers (cumulative)
26.4 Mn
Unique transacting Paisabazaar customers (cumulative)
7.5 Mn
PB Partners advisor network
450,000+ advisors covering ~19,000 PIN codes (~99% of India)
On-ground sales & service presence
Phygital sales support in 200+ cities; on-ground health claims support in 250+ cities
Founded 2008Headquarters Plot No. 119, Sector-44, Gurugram–122001, Haryana, India Company website

How the price took the results

Moved an average of ±2.0% across the last 4 priced result releases

Close before → close after
QuarterReleaseRevenue (₹ Cr) Net profit (₹ Cr)Rev YoYBefore → AfterReaction
Q2 FY2730 Oct 26-89 13−387.1%₹1,018.2 → ₹1,000.1−1.8%
Q1 FY275 Aug 26890 408+2517.6%₹1,597 → ₹1,620+1.4%
Q4 FY266 May 2639 18+5.4%₹1,680.5 → ₹1,701.8+1.3%
Q3 FY262 Feb 2638 16−11.6%₹1,619.1 → ₹1,563.3−3.4%

The move from the last close before each results date to the first close on or after it — the market's first read on the quarter alongside what was filed.

Your own record

Start an Inve Case for PB Fintech Limited

Free account: one company. Everything above stays public.

Write why you follow PB Fintech Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Financial Services companies

PEER COMPARISON
Median ₹47,457 Cr Mkt Cap
₹0 Cr₹20,000 Cr₹40,000 Cr₹60,000 CrPB Fintech Limited (POLICYBZR): ₹44,656 Cr₹44,656 CrPOLICYBZRAuthum Investment & Infrastructure Limited (AIIL): ₹50,257 Cr₹50,257 CrAIIL

Not reported for Mkt Cap: YESBANK, SUNDARMFIN, HDBFS, PIRAMALFIN, 360ONE, MFSL, POONAWALLA

All Financial Services companies → · Financial Services earnings growth →

Quick Answers

Frequently asked questions on PB Fintech Limited

Compiled directly from POLICYBZR's filed financial statements, earnings call transcripts, and ownership disclosures.

How did PB Fintech Limited (POLICYBZR) perform in its latest reported quarter (Sept 2026)?

For the quarter ended Sept 2026, PB Fintech Limited reported revenue of ₹-89 Cr, net profit of ₹13 Cr, an operating margin of −478.0%. Diluted earnings per share stood at ₹0.29.

How is PB Fintech Limited (POLICYBZR) valued today, and what growth does the stock price imply?

PB Fintech Limited (POLICYBZR) trades at ₹953.8, with a market capitalization of ₹44.7k Cr.

Who owns PB Fintech Limited (POLICYBZR) — promoters, FIIs, DIIs, and mutual funds?

As of Sept 2026, FIIs hold 27.1%, DIIs hold 44.9%, Public shareholders hold 27.9%.

Learn to analyse PB Fintech Limited

Guides on how to read this kind of business and the numbers that matter.